Key Takeaways
- Shares of HIMS rallied approximately 13% on April 16, 2026, driven by FDA announcements regarding peptide regulatory review processes
- FDA has scheduled advisory meetings for July 23-24 to assess multiple peptides for potential inclusion on the 503A Bulks List
- Bank of America Securities increased its price target to $25 from $21 while retaining a Neutral rating on the stock
- Analysts view this development as a modest positive for the long term, with minimal near-term earnings impact expected
- Company insiders have offloaded roughly $3.4 million in shares over the last three months without any corresponding purchases
Shares of Hims & Hers Health (HIMS) experienced a significant rally, climbing as high as 13.72% on April 16, 2026, following the FDA’s announcement regarding upcoming advisory committee meetings to assess various wellness peptides currently subject to regulatory restrictions.
Hims & Hers Health, Inc., HIMS
The Food and Drug Administration released a notice confirming that Pharmacy Compounding Advisory Committee meetings are set for July 23 and July 24. These sessions will examine multiple peptide-related bulk drug substances that could potentially be added to the 503A Bulks List. It’s important to note this represents a preliminary procedural milestone rather than actual regulatory approval.
Public statements from RFK Jr. regarding possible FDA regulatory modifications further amplified investor optimism. The agency is considering removing restrictions on as many as 12 peptides, with evaluation processes scheduled to continue through February 2027.
The stock had demonstrated momentum prior to this announcement. Throughout the previous week, HIMS gained approximately 25%, based on InvestingPro data.
Bank of America Increases Valuation Target
Bank of America Securities reacted to the news by raising its price objective on HIMS to $25 from the previous $21 target, though the firm maintained its Neutral rating. The adjustment reflected an increased target valuation multiple to roughly 25.5 times from 21.5 times, attributed to elevated peer multiples and peptide opportunity potential.
BofA highlighted that this development could enable the company to redirect existing GLP-1 compounding infrastructure toward alternative peptides. This consideration holds particular significance given that HIMS has substantial capital invested in GLP-1 facilities following previous FDA compounding limitations.
The investment firm remained measured in its assessment, characterizing the announcement as “an initial small step” while indicating no anticipated near-term earnings impact unless the FDA proceeds with an official determination.
The FDA also emphasized that a majority of the substances under consideration continue to present potential safety concerns under existing guidance.
Additional HIMS Developments
HIMS has recently incorporated Novo Nordisk’s FDA-approved GLP-1 medications into its platform, featuring Wegovy in both injectable and oral formulations. The Wegovy pill represents the sole FDA-approved oral GLP-1 weight loss medication currently on the market.
The platform will additionally provide Ozempic injection pens, though these carry FDA approval exclusively for Type 2 diabetes treatment.
The competitive landscape in the GLP-1 market has intensified significantly. Amazon Pharmacy recently launched same-day delivery service for Eli Lilly’s newly approved GLP-1 medication Foundayo, creating additional competitive pressure for both Novo Nordisk and HIMS.
Regarding insider transactions, CFO Oluyemi Okupe submitted filings to divest shares valued at approximately $4.9 million. Throughout the past three months, company insiders have collectively sold roughly $3.4 million worth of shares, with zero insider purchases documented.
HIMS currently trades at a P/E ratio in the range of 45-47x. According to InvestingPro’s analysis, the stock appears overvalued compared to its Fair Value estimate. The telehealth company maintains a market capitalization of approximately $5.54 billion and serves more than 2 million subscribers.
Bank of America’s EBITDA projection for 2026 stands roughly 21% beneath Wall Street consensus estimates, a discrepancy the firm has previously highlighted in its research coverage.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
